|
|
Phase II Study of Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Patients Who Are Undergoing Treatment for Supratentorial Glioma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Diagnostic, Treatment
|
|
|
|
Closed
|
|
|
|
Over 18
|
|
|
|
NCI
|
|
|
|
UCSF-05106 NCT00274755
|
|
|
Special Category:
SPORE trial Objectives - Determine the magnetic resonance spectroscopic imaging (MRSI) characteristics of patients who are undergoing treatment for supratentorial glioma.
- Determine the survival of patients who undergo magnetic resonance imaging and MRSI.
- Determine the clinical outcome of patients who undergo these imaging procedures.
- Correlate measures of metabolic tumor burden (i.e., CNI, CCCrI, CrNI, and LLI) with survival and clinical outcome in patients who undergo these imaging procedures.
- Determine the time to clinical progression in patients who undergo these imaging procedures.
Entry Criteria Disease Characteristics:
- Histologically confirmed supratentorial glioma
- Grade II-IV disease
- Previously untreated disease
- Eligible for surgical resection and/or chemotherapy with or without radiotherapy
- Tumor accessible by magnetic resonance spectroscopic imaging
Prior/Concurrent Therapy:
- No prior chemotherapy
- No prior radiotherapy
- No prior treatment for the malignancy
Patient Characteristics:
- Karnofsky performance status 60-100%
- Life expectancy ≥ 8 weeks
- Not pregnant
- No contraindication for magnetic resonance examinations, including any of the following:
- Cardiac pacemaker or fibrillator
- Aneurysm clip
- Insulin or infusion pump
- Any implant held in place by a magnet
- Metal contamination anywhere in the body
Expected Enrollment 250A total of 250 patients will be accrued for this study. Outcomes Primary Outcome(s)Survival Time to clinical progression
Outline Patients are assigned to 1 of 2 treatment groups based on grade of disease. - Group 1 (patients with grade II glioma): Patients undergo magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI). Patients then receive chemotherapy. Patients undergo repeat MRI/MRSI after courses 2 and 4 of chemotherapy.
- Group 2 (patients with grade III-IV glioma): Patients undergo MRI/MRSI and then undergo surgical resection of the tumor. Patients then receive chemoradiotherapy. Patients undergo repeat MRI/MRSI within 2 weeks and at 2 months after completion of radiotherapy.
Patients are followed for recurrence, disease progression, and survival.
Trial Contact Information
Trial Lead Organizations UCSF Helen Diller Family Comprehensive Cancer Center | | | Sarah Nelson, PhD, Principal investigator | | | |
Registry Information | | Official Title | | Improved Characterization of Brain Tumors By MRI and MRS | | Trial Start Date | | 2003-11-20 | | Trial Completion Date | | 2007-04-30 (estimated) | | Registered in ClinicalTrials.gov | | NCT00274755 | | Date Submitted to PDQ | | 2005-07-14 | | Information Last Verified | | 2007-04-06 | | NCI Grant/Contract Number | | CA82103, CA58223 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|